Sartorius Stedim Biotech S.A. (DIM.PA) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. DIM.PA files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 14.95% | 30.00% | Pass |
| Interest-bearing investments | 2.34% | 30.00% | Pass |
| Non-permissible income | 0.39% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 34.74% | 33.00% | Fail |
| Interest-bearing investments | 5.44% | 33.00% | Pass |
| Non-liquid assets | 92.31% | at least 20.00% | Pass |
| Non-permissible income | 0.39% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 34.74% | 33.33% | Fail |
| Cash + interest-bearing securities | 5.44% | 33.33% | Pass |
| Accounts receivable | 7.69% | 33.33% | Pass |
| Non-permissible income | 0.39% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 34.74% | 33.33% | Fail |
| Cash + interest-bearing securities | 5.44% | 33.33% | Pass |
| Accounts receivable | 7.69% | 50.00% | Pass |
| Non-permissible income | 0.39% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 15.14% | 33.00% | Pass |
| Cash + interest-bearing securities | 2.37% | 33.00% | Pass |
| Accounts receivable | 0.98% | 33.00% | Pass |
| Non-permissible income | 0.39% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 14.88% | 33.00% | Pass |
| Cash + interest-bearing securities | 2.33% | 49.00% | Pass |
| Accounts receivable | 0.96% | 49.00% | Pass |
| Non-permissible income | 0.39% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 14.88% | 33.33% | Pass |
| Cash + interest-bearing securities | 2.33% | 33.33% | Pass |
| Accounts receivable | 3.29% | 49.00% | Pass |
| Non-permissible income | 0.39% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 49.40 | NEUTRAL |
| Stochastic %K (14) | 12.99 | BUY |
| CCI (20) | -57.70 | NEUTRAL |
| Williams %R (14) | -87.01 | BUY |
| MACD (12,26,9) | -1.38 | SELL |
| ROC (10) | -4.63 | SELL |
| Momentum (10) | -9.10 | SELL |
| EMA (10) | 190.82 | SELL |
| SMA (10) | 193.07 | SELL |
| EMA (20) | 189.53 | SELL |
| SMA (20) | 191.20 | SELL |
| EMA (30) | 187.44 | BUY |
| SMA (30) | 186.16 | BUY |
| EMA (50) | 184.20 | BUY |
| SMA (50) | 182.54 | BUY |
| EMA (100) | 180.77 | BUY |
| SMA (100) | 175.89 | BUY |
| EMA (200) | 183.94 | BUY |
| SMA (200) | 182.15 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Medical Instruments & Supplies
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.